Table I.
Patient demographic and clinical characteristics.
| Group | ||||
|---|---|---|---|---|
| Characteristic | HC | CHB | LC | HCC |
| Total, n | 47 | 137 | 169 | 187 |
| Age, mean years ± SD | 39±12.1 | 34±10.6 | 46±10.2 | 48±10.6 |
| Gender ratio, M:F | 39:8 | 110:27 | 131:38 | 144:43 |
| HBeAg status, n | ||||
| HBeAg positive | NA | 87 | 45 | 42 |
| HBeAg negative | NA | 50 | 124 | 145 |
| HBV DNA, mean logIU/ml ± SD | NA | 3.26±2.25 | 2.90±2.72 | 3.35±2.71 |
| ALT, mean IU/l ± SD | 19.80±13.17 | 131.33±181.22 | 101.78±177.24 | 53.64±66.04 |
| AFP, mean ng/ml ± SD | 4.48±1.29 | 16.15±43.35 | 104.08±186.30 | 492.61±544.00 |
| AFP status, n | ||||
| AFP negative | NA | NA | 64 | 65 |
| AFP positive | 105 | 122 | ||
| hs-CRP, mean mg/l ± SD | 0.59±0.53 | 1.53±2.70 | 2.83±3.05 | 17.34±22.61 |
| Child class (A:B:C), % | NA | NA | 47:53:69 | 52:75:60 |
| MELD score, mean ± SD | NA | NA | 9.0±6 | 11.5±4 |
| TNM stage, n | ||||
| I–II | NA | NA | NA | 109 |
| III–IV | 78 | |||
| Metastasis, n | ||||
| Yes | NA | NA | NA | 123 |
| No | 64 | |||
The diagnostic cutoff values of AFP was 20 ng/l. HCC, hepatocellular carcinoma; CHB, chronic hepatitis B virus; LC, liver cirrhosis; HC, healthy control; AFP, α-fetoprotein; MELD, model for end-stage liver disease; ALT, alanine aminotransferase; hs-CRP, high-sensitivity C-reactive protein; AFP, α-fetoprotein; HBV DNA, hepatitis B virus deoxyribose nucleic acid; HbeAg, hepatitis B eantigen; NA, not applicable; SD, standard deviation; TNM, tumor-node-metastasis.